SCHEMBL6510185

SCHEMBL6510185

C(=NNc1nc2nonc2nc1NCc1ccccc1)c1ccc(-c2ccccc2)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.50
MAPT P10636 13/20 0.45
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 4/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
TLR9 Q9NR96 1/20 0.45
PHGDH O43175 1/20 0.42
KDM4E B2RXH2 6/20 0.42
LMNA P02545 5/20 0.42
HPGD P15428 4/20 0.41
ALOX12 P18054 1/20 0.41
GFER P55789 1/20 0.40
GAA P10253 2/20 0.39
THRB P10828 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 3/20 0.39
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421076 0.93 MAPT (0.50) BIRC5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6421081 0.93 MAPT (0.50) BIRC5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6419253 0.91 PHGDH (0.57) BIRC5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6419258 0.91 PHGDH (0.57) BIRC5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6435171 0.88 BIRC5 (0.68) BIRC5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6435175 0.88 BIRC5 (0.68) BIRC5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6438197 0.87 MAPT (0.52) BIRC5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6438200 0.87 MAPT (0.52) BIRC5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6432659 0.87 BIRC5 (0.59) BIRC5MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6432656 0.87 BIRC5 (0.59) BIRC5MAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885MAPT 4420/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.